|
1
|
Huitzil-Melendez FD, Capanu M, O'Reilly
EM, Duffy A, Gansukh B, Saltz LL and Abou-Alfa GK: Advanced
hepatocellular carcinoma: Which staging systems best predict
prognosis? J Clin Oncol. 28:2889–2895. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
No authors listed: A new prognostic system
for hepatocellular carcinoma: a retrospective study of 435
patients: the Cancer of the Liver Italian Program (CLIP)
investigators. Hepatology. 28:751–755. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Poon D, Anderson BO, Chen LT, Tanaka K,
Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, et al:
Asian Oncology Summit: Management of hepatocellular carcinoma in
Asia: Consensus statement from the Asian Oncology Summit 2009.
Lancet Oncol. 10:1111–1118. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takanishi DM Jr, Severino R and Wong LL:
The Cancer of the Liver Italian Program (CLIP) score: Validation of
a new prognostic system for hepatocellular carcinoma. Hawaii Med J.
66:209–212. 2007.PubMed/NCBI
|
|
5
|
Levy I and Sherman M: Liver Cancer Study
Group of the University of Toronto. Staging of hepatocellular
carcinoma: Assessment of the CLIP, Okuda, and Child-Pugh staging
systems in a cohort of 257 patients in Toronto. Gut. 50:881–885.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Llovet JM, Brú C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marrero JA, Fontana RJ, Barrat A, Askari
F, Conjeevaram HS, Su GL and Lok AS: Prognosis of hepatocellular
carcinoma: Comparison of 7 staging systems in an American cohort.
Hepatology. 41:707–716. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cillo U, Vitale A, Grigoletto F, Farinati
F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'Amico F, et
al: Prospective validation of the Barcelona Clinic Liver Cancer
staging system. J Hepatol. 44:723–731. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bruix J, Sherman M, Llovet JM, Beaugrand
M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M
and Rodés J: EASL Panel of Experts on HCC; European Association for
the Study of the Liver: Clinical management of hepatocellular
carcinoma. Conclusions of the Barcelona-2000 EASL conference. J
Hepatol. 35:421–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kudo M, Chung H and Osaki Y: Prognostic
staging system for hepatocellular carcinoma (CLIP score): Its value
and limitations, and a proposal for a new staging system, the Japan
Integrated Staging Score (JIS score). J Gastroenterol. 38:207–215.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
No authors listed: Liver Cancer Study
Group of Japan: The general rules for the clinical and pathological
study of primary liver cancer. Jpn J Surg. 19:98–129. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kudo M, Chung H, Haji S, Osaki Y, Oka H,
Seki T, Kasugai H, Sasaki Y and Matsunaga T: Validation of a new
prognostic staging system for hepatocellular carcinoma: The JIS
score compared with the CLIP score. Hepatology. 40:1396–1405. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gomaa AI, Hashim MS and Waked I: Comparing
staging systems for predicting prognosis and survival in patients
with hepatocellular carcinoma in Egypt. PLoS One. 9:e909292014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leung TW, Tang AM, Zee B, Lau WY, Lai PB,
Leung KL, Lau JT, Yu SC and Johnson PJ: Construction of the Chinese
University Prognostic Index for hepatocellular carcinoma and
comparison with the TNM staging system, the Okuda staging system,
and the Cancer of the Liver Italian Program staging system: A study
based on 926 patients. Cancer. 94:1760–1769. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Henderson JM, Sherman M, Tavill A,
Abecassis M, Chejfec G and Gramlich T: AHPBA/AJCC consensus
conference on staging of hepatocellular carcinoma: Consensus
statement. HPB Oxf. 5:243–250. 2003. View Article : Google Scholar
|
|
16
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abdel-Rahman O and Fouad M:
Sorafenib-based combination as a first line treatment for advanced
hepatocellular carcinoma: A systematic review of the literature.
Crit Rev Oncol Hematol. 91:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takeda H, Nishikawa H, Osaki Y, Tsuchiya
K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y and Izumi N:
Japanese Red Cross Liver Study Group: Clinical features associated
with radiological response to sorafenib in unresectable
hepatocellular carcinoma: a large multicenter study in Japan. Liver
Int. 35:1581–1589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Llovet JM, Peña CE, Lathia CD, Shan M,
Meinhardt G and Bruix J: SHARP Investigators Study Group: Plasma
biomarkers as predictors of outcome in patients with advanced
hepatocellular carcinoma. Clin Cancer Res. 18:2290–2300. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishikawa H, Osaki Y, Endo M, Takeda H,
Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, et al:
Japanese Red Cross Liver Study Group: Comparison of standard-dose
and half-dose sorafenib therapy on clinical outcome in patients
with unresectable hepatocellular carcinoma in field practice: A
propensity score matching analysis. Int J Oncol. 45:2295–2302.
2014.PubMed/NCBI
|
|
22
|
Bruix J and Sherman M: Practice Guidelines
Committee, American Association for the Study of Liver Diseases.
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamasaki T, Kurokawa F, Shirahashi H,
Kusano N, Hironaka K and Okita K: Percutaneous radiofrequency
ablation therapy with combined angiography and computed tomography
assistance for patients with hepatocellular carcinoma. Cancer.
91:1342–1348. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park JW, Amarapurkar D, Chao Y, Chen PJ,
Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, et al:
Consensus recommendations and review by an International Expert
Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver
Int. 33:327–337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kudo M: Targeted therapy for liver cancer:
Updated review in 2012. Curr Cancer Drug Targets. 12:1062–1072.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shingina A, Hashim AM, Haque M, Suen M,
Yoshida EM, Gill S, Donnellan F and Weiss AA: In a ‘real-world’,
clinic-based community setting, sorafenib dose of 400 mg/day is as
effective as standard dose of 800 mg/day in patients with advanced
hepatocellular carcinoma, with better tolerance and similar
survival. Can J Gastroenterol. 27:393–396. 2013.PubMed/NCBI
|
|
28
|
Ueno S, Tanabe G, Sako K, Hiwaki T,
Hokotate H, Fukukura Y, Baba Y, Imamura Y and Aikou T:
Discrimination value of the new western prognostic system (CLIP
score) for hepatocellular carcinoma in 662 Japanese patients.
Cancer of the Liver Italian Program. Hepatology. 34:529–534. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanley JA and McNeil BJ: The meaning and
use of the area under a receiver operating characteristic (ROC)
curve. Radiology. 143:29–36. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pencina MJ and D'Agostino RB: Overall C as
a measure of discrimination in survival analysis: Model specific
population value and confidence interval estimation. Stat Med.
23:2109–2123. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maetani S, Onodera H, Nishikawa T and Tobe
T: Systematic computer-aided search of optimal staging system for
colorectal cancer. J Clin Epidemiol. 44:285–291. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Grieco A, Pompili M, Caminiti G, Miele L,
Covino M, Alfei B, Rapaccini GL and Gasbarrini G: Prognostic
factors for survival in patients with early-intermediate
hepatocellular carcinoma undergoing non-surgical therapy:
Comparison of Okuda, CLIP, and BCLC staging systems in a single
Italian centre. Gut. 54:411–418. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu ZZ, Wang D, Cong WM, Jiang H, Yu Y,
Wen BJ, Dong H, Zhang X, Liu SF, Wang AZ, et al: Sex-related
differences in DNA copy number alterations in hepatitis B
virus-associated hepatocellular carcinoma. Asian Pac J Cancer Prev.
13:225–229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cillo U, Bassanello M, Vitale A,
Grigoletto FA, Burra P, Fagiuoli S, D'Amico F, Ciarleglio FA,
Boccagni P, Brolese A, et al: The critical issue of hepatocellular
carcinoma prognostic classification: Which is the best tool
available? J Hepatol. 40:124–131. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Collette S, Bonnetain F, Paoletti X,
Doffoel M, Bouché O, Raoul JL, Rougier P, Masskouri F, Bedenne L
and Barbare JC: Prognosis of advanced hepatocellular carcinoma:
Comparison of three staging systems in two French clinical trials.
Ann Oncol. 19:1117–1126. 2008. View Article : Google Scholar : PubMed/NCBI
|
